Serotonin receptor 2 angonist - Pipeline Insight, 2022

This “Serotonin receptor 2 Agonist - Pipeline Insight, 2022” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Serotonin receptor 2 Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Serotonin receptor 2 Agonist Understanding

Serotonin receptor 2 Agonist: Overview

Serotonin receptors are Endogenous compounds and drugs that bind to and activate serotonin receptors. Many serotonin receptor agonists are used as antidepressants; anxiolytics; and in the treatment of migraine disorders.

Function - Serotonin 5-HT2A receptors (5-HT2ARs) are widely distributed in the central nervous system, especially in brain region essential for learning and cognition. The serotonin (5-HT) 5-HT2A receptor (5-HT2AR) is a GPCR of the type A family. Within the brain this receptor participates in processes such as cognition and working memory, been implicated in effective disorders such as schizophrenia, and mediate the primary effects of hallucinogenic drugs. In the periphery, receptors have been linked to vasoconstriction and hypertension, and to inflammatory processes that can lead to atherosclerosis.

Serotonin receptor 2 Agonist- Agonists acting at 5-HT2A receptors located on the apical dendrites of pyramidal cells within regions of the prefrontal cortex are believed to mediate hallucinogenic activity.

Serotonin receptor 2 Agonist Emerging Drugs Chapters

This segment of the Serotonin receptor 2 Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Serotonin receptor 2 Agonist Emerging Drugs

Aripiprazole: Bristol Myers Squibb

Aripiprazole functions as a partial agonist at the dopamine D2 and the serotonin 5-HT1A receptors. Dopamine and serotonin are natural compounds called neurotransmitters, and are involved in transmitting messages between brain cells. The drug is being evaluated in phase III for the treatment of Pervasive child development disorders and agitation.

Psilocybin: COMPASS Pathways

Psilocybin therapy is an approach being investigated for the treatment of mental health challenges. It combines the pharmacological effects of psilocybin, a psychoactive substance, with psychological support. The therapy is under investigation in phase II stage of development for the treatment of patients with bipolar depression and other depressive disorders.

Serotonin receptor 2 Agonist: Therapeutic Assessment

This segment of the report provides insights about the different Serotonin receptor 2 Agonist drugs segregated based on following parameters that define the scope of the report.

Major Players working on Serotonin receptor 2 Agonist

There are approx. 5+ key companies which are developing the Serotonin receptor 2 Agonist. The companies which have their Serotonin receptor 2 Agonist drug candidates in the most advanced stage, i.e. preregistration include, Bristol Myers Squibb.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Serotonin receptor 2 Agonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Serotonin receptor 2 Agonist: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Serotonin receptor 2 Agonist therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Serotonin receptor 2 Agonist drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Serotonin receptor 2 Agonist R&D. The therapies under development are focused on novel approaches for Serotonin receptor 2 Agonist.

Serotonin receptor 2 Agonist Report Insights

• Serotonin receptor 2 Agonist Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Serotonin receptor 2 Agonist Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Serotonin receptor 2 Agonist drugs?
• How many Serotonin receptor 2 Agonist drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Serotonin receptor 2 Agonist?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Serotonin receptor 2 Agonist therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Serotonin receptor 2 Agonist and their status?
• What are the key designations that have been granted to the emerging drugs?